Publicacións en colaboración con investigadores/as de Christie Hospital NHS Foundation Trust (17)

2024

  1. Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease

    Annals of Surgical Oncology, Vol. 31, Núm. 10, pp. 6495-6503

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  3. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2022

  1. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  2. Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry

    Cancers, Vol. 14, Núm. 10

  3. Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

    ESMO Open, Vol. 7, Núm. 1

  4. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

    Nature medicine, Vol. 28, Núm. 4, pp. 752-765

2021

  1. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

  2. Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System

    Hepatology, Vol. 73, Núm. 6, pp. 2311-2325

  3. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  4. Next-generation biomarkers for cholangiocarcinoma

    Cancers, Vol. 13, Núm. 13

  5. REPLY:

    Hepatology

  6. REPLY:

    Hepatology

  7. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic

    Expert Opinion on Investigational Drugs, Vol. 30, Núm. 4, pp. 377-388

2020

  1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

    Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588

  2. Current and novel therapeutic opportunities for systemic therapy in biliary cancer

    British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059